Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplant

References

• Harousseau JL. Hematopoietic stem cell transplantation in multiple myeloma. J Natl Compr Canc Netw 2009;7:961–970.
   PubMed Web of Science ®Google Scholar
• Giralt S, Stadtmauer EA, Harousseau JL, et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 2009;23:1904–1912.
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Moreau P. Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 2009;360: 2645–2654.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Ingle JN, Litzow MR, et al. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant 2001;28:865–871.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Gertz MA, Litzow MR, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. Clin Cancer Res 2005;11:1210–1218.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Gertz MA, Inwards DJ, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001;98:579–585.
   PubMed Web of Science ®Google Scholar
• Behl D, Ristow K, Markovic SN, et al. Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. Br J Haematol 2007;137:409–415.
   PubMed Web of Science ®Google Scholar
• Behl D, Porrata LF, Markovic SN, et al. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 2006;20:29–34.
   PubMed Web of Science ®Google Scholar
• De Angulo G, Hernandez M, Morales-Arias J, et al. Early lymphocyte recovery as a prognostic indicator for high-risk Ewing sarcoma. J Pediatr Hematol Oncol 2007;29:48–52.
   PubMed Web of Science ®Google Scholar
• Rochet NM, Kottschade LA, Grotz TE, et al. The prognostic role of the preoperative absolute lymphocyte count and absolute monocyte count in patients with resected advanced melanoma. Am J Clin Oncol 2013 Jun 14. [Epub ahead of print]
   Google Scholar
• Kay NE, Leong TL, Bone N, et al. Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients. Blood 2001;98:23–28.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Gertz MA, Geyer SM, et al. The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2004;18:1085–1092.
   PubMed Web of Science ®Google Scholar
• Ege H, Gertz MA, Markovic SN, et al. Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study. Br J Haematol 2008;141:792–798.
   PubMed Web of Science ®Google Scholar
• Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115–1123.
   Google Scholar
• Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–1473.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Goldschmidt H, Rosinol L, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 2013;31:3279–3287.
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL. The role of high-dose therapy with autologous stem cell support in the era of novel agents. Semin Hematol 2009;46:127–132.
   PubMed Web of Science ®Google Scholar
• De Angulo G, Yuen C, Palla SL, et al. Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies. Cancer 2008;112:407–415.
   PubMed Web of Science ®Google Scholar
• Storek J, Dawson MA, Storer B, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001;97:3380–3389.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Litzow MR, Markovic SN. Immune reconstitution after autologous hematopoietic stem cell transplantation. Mayo Clin Proc 2001;76:407–412.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Gastineau DA, Padley D, et al. Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation. Leuk Lymphoma 2003;44:997–1000.
   PubMed Web of Science ®Google Scholar
• Raitakari M, Brown RD, Gibson J, et al. T cells in myeloma. Hematol Oncol 2003;21:33–42.
   PubMed Web of Science ®Google Scholar
• Sze DM, Brown RD, Yuen E, et al. Clonal cytotoxic T cells in myeloma. Leuk Lymphoma 2003;44:1667–1674.
   PubMed Web of Science ®Google Scholar
• Abbas AK, Ratnofsky SE, Burakoff SJ. T lymphocyte-mediated suppression of myeloma function in vitro. II. Evidence for regulation of hapten-binding myelomas by syngeneic hapten-specific cytolytic T lymphocytes. J Exp Med 1980;152:306–323.
   Google Scholar
• Abbas AK, Perry LL, Bach BA, et al. Idiotype-specific T cell immunity. I. Generation of effector and suppressor T lymphocytes reactive with myeloma idiotypic determinants. J Immunol 1980; 124:1160–1166.
   Google Scholar
• Abbas AK. Antigen and T lymphocyte mediated suppression of myeloma cells: model systems for regulation of lymphocyte function. Immunol Rev 1979;48:245–264.
   PubMed Web of Science ®Google Scholar
• Paglieroni T, MacKenzie MR. In vitro cytotoxic response to human myeloma plasma cells by peripheral blood leukocytes from patients with multiple myeloma and benign monoclonal gammopathy. Blood 1979;54:226–237.
   PubMed Web of Science ®Google Scholar